NeokBio Leads Development
Phase 1 Clinical Trials Targeted to Begin Mid-Year

ABL Bio, a company specializing in bispecific antibodies, announced on February 2 that it submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) on January 30 (local time) for a Phase 1 clinical trial of its bispecific antibody-drug conjugate (ADC) candidate, ABL209 (NEOK002).


ABL209 is an ADC candidate that combines a bispecific antibody targeting both EGFR and MUC1?proteins expressed on the surface of cancer cells?with a topoisomerase I inhibitor. According to the company, non-clinical studies have demonstrated superior anti-cancer efficacy compared to ADCs based on single antibodies.

ABL Bio company logo image. ABL Bio

ABL Bio company logo image. ABL Bio

View original image

The global clinical development of ABL209 is being led by NeokBio, a bispecific antibody ADC development company established by ABL Bio in the United States. NeokBio holds global development and commercialization rights for both ABL209 and ABL206 (NEOK001).


ABL206 received IND approval from the FDA for a Phase 1 clinical trial last month. NeokBio plans to initiate Phase 1 clinical trials for both candidates around mid-2026 and release early clinical data during 2027.


ABL Bio is developing multiple clinical and preclinical pipelines based on its bispecific antibody platform, Grabody. Currently, nine pipelines?ABL301, ABL001, ABL111, ABL503, ABL105, ABL104, ABL103, ABL202, and ABL206?are in clinical stages in the United States, China, Australia, and Korea.



The subsequent clinical trials for ABL301 are being conducted by Sanofi. ABL001 has received Fast Track designation from the FDA. ABL111 has shown initial efficacy data in combination immuno-oncology clinical trials.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing